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BAckground: In Mexico breast cancer reported an incidence of 13,939 cases 
and 5,217 mortality cases in 2008. Between 40-50% of those cases are diagnosed 
in stages III and IV. oBjectives: The aim of this study was to assess a cost-effec-
tiveness analysis for the use of fulvestrant 500mg as a therapy for postmenopausal 
women with locally advanced or metastatic breast cancer with ER+ receptor and 
prior progression on endocrine therapy, from Public Health Sector perspective in 
Mexico. Methods: A cost-effectiveness analysis was performed using a Markov 
model with a time horizon of 1 and 5 years according to a prior economic evalua-
tion and based on the results from CONFIRM study. Two cohorts of treatment were 
compared; Cohort A contemplates the addition of fulvestrant to the standard treat-
ment and Cohort B the standard treatment. The effectiveness was measured as Life 
years Gained (LY). The use of resources was determined from the clinical practice 
in Mexico and costs were obtained from institutional sources. results: The ICER 
per LY for 1 year time horizon was $9,609 for Cohort A versus Cohort B. The fifth 
year implies an ICER of $6,581, being in both cases an ICER below the willingness 
to pay in Mexico (1 GDP: $10,000USD). conclusions: Based on the findings the 
use of fulvestrant is a cost-effective strategy that provides a longer period of stable 
disease, an improvement in LY, diminish the use of chemotherapy and optimize 
institutional resources.
PCN113
AssessmeNt Cost-effeCtiveNess of PegfilgrAstim ANd filgrAstim iN 
PediAtriC PAtieNts with solid tumors
Medina Barajas F.P.1, Sánchez Zubieta F.2, Islas Carbajal M.C.3, Pardo Zepeda M.1,  
Ramírez Urenda X.2, Rincón Sánchez A.R.3
1Universidad de Guadalajara, Guadalajara, Mexico, 2Hospital Civil de Guadalajara, Guadalajara, 
Mexico, 3CUCS, Universidad de Guadalajara, Guadalajara, Mexico
oBjectives: Evaluate the cost- effectiveness of pegfilgrastim compared with fil-
grastim relationship in preventing febrile neutropenia in pediatric patients with 
solid tumors. Methods: Retrospective cohort study from 2012 to 2014, and was 
made micro-cost technic. Records of pediatric patients diagnosed with solid tumors 
receiving pegfilgrastim and filgrastim post-chemotherapy for prevention of febrile 
neutropenia were evaluated. Febrile neutropenia is considered as an event with 
absolute neutrophil count less than 1000 cells per milliliter blood and fever ≤ 38.2°C. 
This study adheres to the principles of the Declaration of Helsinki, followed good 
clinical practices and has been approved by Hospital bioethics committee. results: 
120 and 152 cases of pegfilgrastim and filgrastim respectively were included. The 
mean age was 9 years, 63 % male and 47 % female. The absolute neutrophil count 
was 6,204 with pegfilgrastim and filgrastim 2,332. Filgrastim was more effective 
cost $ 1195 pesos per thousand neutrophils, in cases where lower doses were 
administered to 200 micrograms per maximum 7 days. The cost-effectiveness of 
pegfilgrastim was $ 2,484 per thousand neutrophils, reaching a cost effective advan-
tage in cases of patients over 40 kilos would require 7 to 14 doses of filgrastim. No 
significant differences in the effectiveness of pegfilgrastim and filgrastim in post-
chemotherapy preventing neutropenia were observed. conclusions: Filgrastim 
maintains effective cost advantage over pegfilgrastim when the dose is less than 
200 micrograms in a treatment period of at least 7 days
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oBjectives: A randomized clinical study compare effects of pre-operative eicosap-
entaenoic acid enriched oral nutritional supplement (EPA-ONS) along with 5-weeks 
radio-chemotherapy to 5-weeks radio-chemotherapy only on survival and quality 
of life and safety had been completed and the results were published elsewhere. 
This abstract aimed evaluate cost effectiveness of 5-week EPA ONS usage com-
pared to no nutritional supplement in terms of survival. Methods: A total 80 colo-
rectal carcinoma patients had been randomized to 5-week radio-chemotherapy 
(FUFA+EBRT)+EPA ONS (2 package per day) or radio-chemotherapy (FUFA+EBRT) 
only equally by stratifying age, gender, nutritional status and radiotherapy method. 
In study time horizon, survival was evaluated by Kaplan Maier estimator and expo-
nential parametric regression model (best fitting model based on AIC-BIC) was used 
to extrapolate 10-year survival. Since patients’ characteristics, treatment modalities 
and other procedures were reported to be similar among groups, only cost of EPA 
ONS was taken into cost-analysis which is prepared from perspective of reimburse-
ment institute in Turkey. results: Mean (95% confidence interval) survival time 
was 6.8(6.3-7.3) and 5.5(4.6-6.4) years in EPA-ONS + radio-chemotherapy and radio-
chemotherapy only groups, respectively. Five week EPA-ONS costs 224.6 USD/per 
patient. Incremental cost effectiveness ratio (ICER) for in study period was 234.4 
USD per life-year gained; when 10-year survival model was used ICER was 97.5 USD 
per life-year gained. conclusions: Survival analysis revealed that preoperative 
EPA-ONS usage along with radio-chemotherapy prolonged overall survival. EPA-
ONS appears to be a cost-effective concomitant treatment of radio-chemotherapy 
in patient with colorectal carcinoma.
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oBjectives: To estimate the potential public health impact of a 9-valent HPV 
(human papillomavirus) vaccine (HPV9) in Japan in preventing HPV-related dis-
We developed a decision model comparing IHC/MSI tumor tissue testing (IHC/
MSI), followed by targeted sequencing of the suspected gene to two hypothetical 
universal screening strategies: (1) NGS as a reflex test to IHC/MSI testing if these 
tests suggest a protein abnormality; (3) use of a NGS gene panel in all patients 
with CRC. Outcomes measured were life-years gained, quality adjusted life years 
(QALY) gained, and costs, Sensitivity analyses were conducted to assess uncer-
tainty. results: Compared to the reference strategy, the price per QALY gained 
was $196,000 for universal NGS gene panel testing. When using NGS gene panel as 
a reflex strategy to abnormal IHC/MSI, the price per QALY was $71,000. The most 
influential variables in the one-way sensitivity analysis were the number of relatives 
tested, the prevalence of Lynch syndrome in CRC patients and the cost of CRC sur-
veillance in relatives with Lynch syndrome detected. conclusions: Use of NGS in 
all colorectal cancer patients to detect inherited cancer and inform family members 
is unlikely to be cost-effective despite the lower per base pair sequencing cost of 
NGS. However, NGS may be cost-effective when used as a complement to tumor-
tissue testing strategies. Further studies are needed to validate these findings.
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oBjectives: High-risk, non-muscle-invasive bladder cancer (NMIBC) is heteroge-
neous in its presentation, resulting in patient subpopulations with diverse treat-
ment options. A comprehensive model estimating costs and health outcomes 
with various NMIBC treatment strategies is needed for diverse patient subpopula-
tions. Methods: A Markov model simulating patient outcomes was developed 
based on published treatment guidelines. Health states encompass high-risk NMIBC, 
tumor-free, muscle-invasive progression (MIP), and metastasis. Four patient popula-
tions were considered: (1) high-risk T1 or Ta tumors; (2) Carcinoma in situ (Cis) only; 
(3) high-risk T1/Ta tumors with concomitant Cis; (4) general NMIBC population with 
high-risk T1/Ta tumors and/or Cis. Treatment options include trans-urethral resec-
tion (TUR) and adjuvant intravesical bacillus Calmette-Guérin (BCG), mitomycin C 
(MMC) or valrubicin for populations (1), (3) and (4), or intravesical treatment alone for 
population (2). The model assesses treatments as first- or second-line, or as alterna-
tives for patients intolerant of or refractory to other treatment. Radical cystectomy 
is performed after MIP or repeated treatment failure. Response (in patients with Cis) 
and recurrence rates and percentages of BCG-intolerant/refractory patients were 
estimated from the literature. Costs were obtained from publicly available sources. 
The model was validated against published epidemiology and cost data. results: 
The lifetime cost per person of treating high-risk T1/Ta patients with BCG was within 
20% of costs estimated in published economic models. The lifetime cost per person 
of treating BCG-intolerant/refractory Cis patients with valrubicin was estimated to 
be 45% higher than for cystectomy. Adverse event costs for the general high-risk 
NMIBC population treated with BCG account for 17% of the total treatment cost com-
pared with 5% for MMC. Approximately 40% and 15% of patients treated with BCG 
eventually undergo cystectomy and MIP, respectively. conclusions: This validated 
model can be used to estimate costs and health outcomes associated with existing 
treatment strategies as well as the cost-effectiveness of novel intravesical therapies.
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oBjectives: Fabulous advance in treatment of NSCLC has been made since the late 
1990s, remarkably with the development of targeted drugs such as bevacizumab 
(BEV). Despite of the proved effectiveness and safety of BEV in treatment of NSCLC, 
the high price of drug caused obstacles in using drugs in clinical practice. The cost-
effectiveness of BEV has been evaluated in many countries. However until now there 
isn’t any relevant study has been evaluated. This is the aim of this study. Methods: 
A Markov model has been developed to evaluate the cost-effectiveness of beva-
cizumab in treatment of NSCLC with 3 Markov stages, including stable disease, 
progressive disease and death. The model has a cycle length of 1 year with the time 
horizon of life time. The population of 1000 patients patients, entering the model 
in the SD state, has been evaluated to assess the cost of effectiveness of different 
treatment regimens. The transition rates have been retrieved from clinical trials. The 
prices of drugs and medical services have been retrieved from relevant price-lists of 
major hospitals in Vietnam. The sensitivity analysis has been conducted to evaluate 
the sensitivity of model. results: The cost of BCP and PC regimen for treatment 
of NSCLC accounts for 5,979,573,560 VND and 992,767,115 with the QALY of 10.43 
and 7.24, respectively. The CER of BCP regimens for treatment of NCSLC accounts 
for 573,199,170 VND, which is around 4 times higher than that of PC regimen. The 
ICER of BCP regimen versus PC regimen in treatment of NSCLC accounts for around 
1.56 billion VND, which is around 20 times higher than the willingness-to-pay of 
Vietnam (60 million VND). conclusions: Due to the high cost of drug, combina-
tion of bevacizumab in the PC regimen in treatment of NSCLC is considered not 
cost-effectiven in Vietnam.
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oBjectives: The two most common breast reduction techniques presently used 
in North America are the Vertical Scar Reduction (VSR) and the Inverted T-shaped 
Reduction (ITR). A previous Randomized Controlled Trial (RCT) has shown no clear 
superiority of one over the other in terms of Health-Related Quality of Life (HRQL). 
No economic evaluation has been undertaken however to determine if the VSR 
is more cost-effective than the ITR. Methods: 255 patients were randomized to 
either VSR or ITR immediately pre-operatively. The effectiveness of two techniques 
was measured with the HUI3. Both direct and productivity costs were captured 
parallel to the RCT. Case Report Forms (CRF) captured patient-related costs associ-
ated with the surgery. The human capital method was used to capture productiv-
ity losses. The perspectives of the Ministry of Health (MOH), the patient and the 
Society were considered results: ITR dominated VSR under the MOH perspective 
by being slightly less costly ($3,090.06 vs. $3,106.58) and slightly more effective i.e. 
0.87 Quality Adjusted Life Years (QALY) versus 0.86 QALYs. In the societal and patient 
perspective, VSR was both less costly and less effective. At the commonly quoted 
Canadian threshold of $50,000 per QALY gained, the probability that VSR was cost-
effective was 29.3%, 68.2% and 66.9% under a MOH, patient and societal perspective 
respectively. A subgroup analysis of breast reductions of < 500 grams found that 
the VSR was more likely cost-effective. conclusions: This analysis informs us 
that the VSR is more likely than not, cost-effective from the patient and societal 
perspective but not from the MOH at a willingness-to-pay threshold of $50,000/
QALY. If, however, we were to limit the VSR for those breast reductions in which we 
expect excision of breast tissue < 500 grams per breast, then this technique is more 
likely cost-effective under all perspectives.
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oBjectives: Estimate the incremental cost-effectiveness ratio (ICER) of D+T 
versus vemurafenib and dacarbazine for BRAFV600 mutation-positive MM from 
the UK NHS perspective. Methods: A partitioned-survival model with 3 states 
(progression-free survival [PFS], post-progression survival, and death) and a 
lifetime horizon was developed. Treatment benefits were measured as gains in 
quality-adjusted life-years (QALYs). PFS and overall survival (OS) were derived 
from indirect treatment comparisons (ITCs) of D+T (from the Phase II BRF113220 
study) versus vemurafenib (BRIM-3) and dacarbazine (BREAK-3). Latest OS data 
were adjusted for confounding effects of treatment switching, permitted upon 
progression in all studies. Safety data were from aforementioned trials. Costs were 
from the literature, a physician survey, and assumptions. Costs of medications 
to the NHS (incorporating available patient-access schemes), post-study antican-
cer therapy, routine and adverse event (AE) management, treatment initiation, 
and death were included. Utility data for D+T were derived from BREAK-3, with 
adjustment for differences in response and incidence of AEs. Deterministic and 
probabilistic sensitivity analyses were performed. results: ITCs showed D+T 
significantly improved PFS versus vemurafenib (hazard ratio [HR] 0.38; 95% CI, 
0.19–0.74) and dacarbazine (0.14; 0.08–0.28) and suggested improved OS, although 
not statistically significant (0.42; 0.09–1.97 versus vemurafenib and 0.26; 0.05–1.27 
versus dacarbazine). Treatment with D+T was associated with a gain in QALYs 
versus vemurafenib and dacarbazine. The ICER for D+T was £50,603/QALY versus 
vemurafenib and £49,804/QALY versus dacarbazine. conclusions: Based on 
results of a Phase II trial and an ITC, D+T offers improved PFS and OS versus vemu-
rafenib and dacarbazine. Further, considering NICE’s criteria for life-extending, 
end-of-life treatments, D+T may be cost-effective compared with vemurafenib, 
the NHS’s current standard of care for patients with BRAFV600 mutation-positive 
MM, although conclusions must await ongoing modelling on the basis of the Phase 
III, COMBI-D trial.
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oBjectives: Muscle-invasive bladder cancer (MIBC) is a deadly disease that dis-
proportionately affects the elderly and is treated with bladder removal (i.e. radical 
cystectomy). A novel therapy utilizing chemo-radiation has demonstrated fewer 
adverse effects with comparable survival rates, with the possibility of requiring 
delayed cystectomy. The objective of this study was to examine the cost-utility of 
radical cystectomy compared to chemo-radiation in the treatment of (MIBC) among 
the elderly. Methods: A decision-analytic model from the Medicare payer perspec-
tive followed hypothetical patients ages 65 and older with MIBC, using a 5-year 
time horizon from the start of treatment. Surgery and chemo-radiation toxicity, 
survival, and quality-of-life weights were derived from the clinical literature, and 
costs were derived from 2013 Medicare fee schedules. Sensitivity analyses were per-
formed to address the uncertainty of parameter values. results: In the base-case 
analysis, chemo-radiation was less costly and less effective than radical cystectomy. 
Chemo-radiation resulted in a cost savings of $6,788 per patient whereas cystectomy 
resulted in additional 1.2 quality-adjusted life-years (QALY) per patient. Thus, cys-
tectomy would be preferred with an incremental cost-effectiveness ratio of $5,680 
per QALY. Therefore, at a threshold of $50,000 per QALY, chemo-radiation is not 
cost-effective when compared to radical cystectomy. Overall conclusions remained 
the same in sensitivity analyses, although the model was most dependent on the 
eases including cervical intraepithelial neoplasia grades 1 (CIN 1), grades 2 and 3 
(CIN 2/3), and cervical cancer. Methods: A mathematical model of the transmis-
sion dynamics of HPV infection and disease for the HPV9 vaccine was calibrated 
to Japanese epidemiological data on cervical cancer. Based on global estimates, 
we attributed 70% of cervical cancer to HPV 16 and 18 for the quadrivalent vaccine 
(types 6/11/16/18: HPV4), and 20% to the five additional types in HPV9 (31, 33, 45, 
52, and 58). Other inputs were from public data sources and published literature. 
Vaccine efficacy against the 5 additional HPV types was taken from phase III trial 
results for the HPV9 vaccine. We assessed the incremental public health impact 
of HPV9 over HPV4 based on vaccinating 80% of females by age 12. results: We 
projected that HPV9 vaccination of females could reduce the incidence of cervical 
cancer by 46% over 100 years, relative to 36% for HPV4. HPV9 vaccination relative to 
HPV4 vaccination could prevent an additional 305,000 cases of CIN1, 636,000 cases 
of CIN2/3, and 78,000 cases of cervical cancer in the Japanese population, cumula-
tive over 100 years. conclusions: Protecting the Japanese population against 
HPV infection with an HPV9 vaccination program relative to an HPV4 vaccination 
program can have significant public health benefits in addition to the benefits 
provided by HPV4 vaccination.
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oBjectives: To assess cost-effectiveness of five standardized procedures for breast 
reconstruction to delineate the best reconstructive approach in the post mastectomy 
patients in the settings of non-radiated and radiated chest walls. Methods: A decision 
tree modeled five breast reconstruction procedures from the provider perspective to 
evaluate cost-effectiveness. Procedures included autologous flaps with pedicled tissue, 
autologous flaps with free tissue, latissimus dorsi flap with breast implant, expander 
with implant exchange, and immediate implant placement. All methods were com-
pared to a do-nothing alternative. Data for model parameters was collected through a 
systematic review, and patient health utilities were calculated from an ad-hoc survey of 
reconstructive surgeons. Results were measured in cost (US $2011) per quality-adjusted 
life year (QALY). Univariate sensitivity analyses and Bayesian multivariate probalistic 
sensitivity analysis were conducted. results: Pedicled and free autologous tissue 
reconstruction were cost-effective compared to the do-nothing alternative. Pedicled 
autologous tissue was the slightly more cost-effective of the two. The other procedures 
were not found to be cost-effective. The results were robust to a number of sensitivity 
analyses, although the margin between pedicled and free autologous tissue reconstruc-
tion is small and affected by some parameter values. conclusions: Autologous pedi-
cled tissue was slightly more cost-effective than free tissue reconstruction in radiated 
and non-radiated patients. Implant-based techniques were not cost-effective. This is 
in agreement with the growing trend at academic institutions to encourage autologous 
tissue reconstruction due to its natural recreation of the breast contour, suppleness, 
and resiliency in the setting of radiated recipient beds.
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oBjectives: To the best of our knowledge, till date, US do not market any biosimilar 
for the treatment of chemotherapy induced febrile neutropenia (CIN). With Europe 
and Asia already marketing their biosimilars, it was timely to estimate the value of 
this proposed biosimilar in the US. The primary goal of this comparative technology 
assessment was to estimate the economic value by quantifying the savings offered 
by the biosimilar compared to its reference biological, filgrastim. The secondary goal 
was to highlight the clinical value of a proposed biosimilar with the help of a cost-
effectiveness analysis from a US payer perspective. The biosimilar is compared to 
filgrastim and pegfilgrastim, intended for the treatment of CIN. Methods: A decision 
analytical model was designed and implemented using TreeAge Pro 2013 software. 
The initial cost and clinical estimates were based on a similar model published by 
Eldar-Lissai et al (2008) with modified and updated clinical estimates along with costs 
adjusted to 2013. The model was modified to include a proposed biosimilar expected 
to be released in the U.S. in 2014. Sensitivity analyses, including Monte Carlo probabil-
istic analyses, were conducted to assess the robustness of the model. results: The 
model estimated expected costs for the three therapies to be: $3,092.41, $3,808.81, and 
$5,238.82 for biosimilar filgrastim, originator filgrastim, and pegfilgrastim respectively. 
The estimated savings of the biosimilar is estimated to be $ 716.40 per chemotherapy 
cycle and as per estimated usage, this translates to a total potential savings of $1.2 
billion by the end of 2014. The cost-effectiveness analysis resulted in an ICER of $ 
-3,766.29/day length of stay between biosimilar filgrastim and pegfilgrastim dem-
onstrating clinical value. conclusions: With the new US biosimilar legislation of 
February 2012 and filgrastim losing its patent protection in December 2013, this phar-
macoeconomic analysis is timely and significant for health policy.
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